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Abstract 
Metastatic prostate cancer is an incurable disease. After a period of hormone sensitivity 
that allows for the use of antiandrogens, the disease invariably progresses to a situation 
of androgen-independent growth, which deserves the consideration or the use of 
chemotherapy. As many of these patients are elderly and fragile, treatment with 
chemotherapy is challenging. Therefore, new drugs are required. Preclinical evidence 
supports the role of estrogen receptor (ER) signaling in prostate cancer. In this paper, we 
report the first published evidence of PSA control in a patient with metastatic prostate 
cancer treated with fulvestrant acetate. 
 
Introduction 
In the United States, prostate cancer (PCa) is the second leading cause of cancer death 
in men. Approximately 50% of men with PCa have locally advanced or metastatic disease 
[1], and 30% of patients with apparent localized disease have biochemical relapse after the 
first line of treatment [2]. Androgen ablation therapy is the mainstay treatment for 
metastatic PCa [3]; however, most neoplasms ultimately become androgen refractory, at 
which time virtually no effective therapies are available. Therefore, there is a strong 
demand for alternatives to the treatment of androgen-independent PCa (AIPC). 
Fulvestrant belongs to the SERD class of estrogen receptor (ER) antagonists and has 
shown no estrogen-agonist activity in either preclinical or clinical studies [4, 5]. 
Fulvestrant binds competitively to the ER, inhibits receptor dimerization [6], and reduces 
the receptor’s half-life by increasing protein turnover [7]. Thus, fulvestrant’s mechanism  
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of action is different from that of tamoxifen. In fact fulvestrant is recommended for the 
treatment of ER-positive metastatic breast cancer in postmenopausal women with disease 
progression following acquired tamoxifen resistance [8]. 
Recently, interest in using estrogenic therapies for advanced PCa has reemerged, 
primarily in response to the published results [9]. 
Estrogen receptor beta (ER-β) is the predominant ER subtype expressed in normal 
basal epithelial cells of the prostate, in local PCa, and in PCa metastasized to the lymph 
nodes and bones [10]. It has been shown that it is expressed in abundance in most 
established PCa cell lines, including DU145, which we found to express only the ER-β 
subtype of ER [11, 12]. Collectively, these data suggest that ER-β may confer survival 
advantages to PCa cells [9]. Thus, targeted activation or blockade of ER-β action with 
selective ligands may present an attractive strategy for the therapeutic intervention of 
PCa. Cell growth inhibition of the DU145 prostate cancer cell line by the effect of 
fulvestrant by an ER-β-dependent mechanism has been reported [11]. 
Androgen receptor (AR) expression is retained in a significant proportion of AIPC [13, 
14]. AR seems to be a key protein involved in many cases of AR-dependent PCa and is 
critical for promoting prostate cancer cell growth. Therefore, targeting the AR for down-
regulation or degradation could be a useful approach for decreasing AR-dependent 
prostate cancer cell growth and for treating AIPC [15]. 
Bhattacharyya et al. [16] published interesting results treating prostate cancer cell lines 
with fulvestrant. After 6 days of fulvestrant treatment, a 70% growth inhibition was seen 
in androgen-stimulated LNCaP cells, showing that fulvestrant is a potent AR 
downregulator that can produce significant inhibition of prostate cancer cell growth and 
suggesting a strategy for treating prostate cancer with fulvestrant [16]. Very interesting 
results about the potential insulin growth factor receptor-1 (IGR-1) inhibition with the 
combination of fulvestrant and finasteride have also been published [17]. 
A phase II trial was recently published on the use of fulvestrant in castration-resistant 
prostate cancer patients, and no evidence of activity was detected [18]. 
Clinical Case 
A 83-year-old male patient was diagnosed with a Gleason 6 metastatic prostate cancer to the bones 
in October 2006. Initially, he was treated with goserelin acetate (GA) 10.4 mg-depot quarterly, and oral 
bicalutamide 50 mg on a daily basis and 4 mg of monthly intravenous Zoledronia Acid. 
The initial prostate-specific antigen (PSA) level was 89 ng/ml (<4 ng/ml). After 3 months of 
treatment, the PSA level was reduced to 1.5 ng/ml. In May 2007, the PSA level was raised to 17 ng/ml; 
subsequently, GA was discontinued and the daily dose of bicalutamide was increased to 150 mg. In May 
2008, the PSA level reached the level of 120 ng/ml, and the patient began to suffer from bone pain. 
Bicalutamide was stopped and, as the patient refused the possibility of chemotherapy with docetaxel 75 
mg/m
2 every 3 weeks and oral prednisone 5 mg twice daily, he was offered treatment continuation with 
oral cyproterone acetate 50 mg every 8 h. In September 2008, the PSA level was 334 ng/ml, and the 
patient began to suffer from bone pain. We discussed different treatment possibilities with the patient 
and decided to request authorization of the Spanish Health Authorities for treatment with fulvestrant 
under compassionate use, based on our previous experience with 2 other patients. 
After we had received authorization, we began treatment with a loading dose strategy, namely 500 
mg intramuscularly (IM) every 2 weeks during the first month, and 250 mg IM monthly thereafter. This 
strategy follows the CONFIRM study, as a dose-response existence is supposed for fulvestrant [19, 20]. 
The first dose was administered in October 2008. After completion of the first month, the PSA level 
fell to 226 ng/ml, and in January 2008, the PSA level was 154 ng/ml (fig. 1). The patient’s analgesia  
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requirements also diminished. Fulvestrant has not been combined with any other drug. No side effect 
has been documented. 
Discussion 
Treatment of AIPC is a current challenge in oncology. Docetaxel-based chemotherapy 
has demonstrated capacity for increasing overall survival in AIPC [21], but its side effects 
are relevant. Many of our patients are elderly and fragile men with significant 
comorbidities. It is urgent to have new agents with new mechanisms of action available in 
the clinic for the management of metastatic PCa that do not bear a potentially high cost in 
terms of side effects for these patients. Fulvestrant is an interesting drug to be studied in 
this context because of its novel mechanism of action and its low side-effect profile. 
The present case report is our third PSA response to fulvestrant in PCa. The observed 
activity is impressive. Any relevant side effect has been recorded following the adverse 
effects reported by Chadha et al. [18] in their phase II trial. This group did not describe 
any relevant toxicity in any of their recruited patients. 
In view of this reported activity we consider it justified to continue with the 
investigation of fulvestrant in patients with advanced PCa and with the inclusion of 
fulvestrant in the design of future trials for the treatment of PCa. We are beginning to 
treat similar patients with fulvestrant, and we will communicate our results in future 
papers. 
 
 
 
 
 
Fig. 1. PSA level dynamics. 
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